Cidara Therapeutics to Participate in the World Antiviral Congress 2022
SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeff Stein, Ph.D., President and CEO, will participate in a panel discussion at the World Antiviral Congress being held in San Diego, California from November 28-December 1, 2022.
The panel will discuss pandemic preparedness and therapeutic approaches, including predictions on the next viral threat, development of broad-spectrum drugs and platforms to engineer novel therapeutics.
Title: Therapeutic approaches to pandemic preparedness
To register and view the full congress schedule, visit the World Antiviral Congress’ website here.
About Cidara Therapeutics
Testing in Asterisk
MSPs and the POTS Replacement Opportunity
Solutions Showcase TBA